Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low‐grade non‐Hodgkin's lymphoma

Abstract

In the last few years the research for new biological features in low‐grade non‐Hodgkin's lymphoma has provided important results. Several biological parameters are under evaluation and, in particular, cytokines and soluble receptors levels are showing their importance as prognostic parameters. In the present study, serum levels of tumor necrosis factor alpha (TNF‐α) and soluble CD23 (sCD23) were measured at the time of diagnosis and after induction polychemotherapy in 40 patients with newly diagnosed low‐grade non‐Hodgkin's lymphoma (LG‐NHL). The treaments were CIOP (cyclophosphamide, idarubicin, vincristine, prednisone) regimen for 28 patients and FMP (fludarabine, mitoxantrone, prednisone) scheme for 12 patients. Pretreatment levels of TNF‐α were highly elevated in patients with LG‐NHL compared with healthy controls (p=0.005) and were significantly correlated with the Ann Arbor stage (p=0.001). sCD23 was detected in 35 patients at diagnosis and were markedly increased in LG‐NHL patients when compared to healthy controls (p=0.005); patients with advanced stage presented higher values than those with early stage disease (p=0.002). All the complete responders (20/40, 50%) showed a decrease of TNF‐α and sCD23 levels. By contrast, the combination of high levels of TNF‐α and sCD23 correspond to a group of non‐responders. Our results suggest that TNF‐α and sCD23 are specific prognostic parameters for LG‐NHL, and that they could be used as tumor markers within a potential biological prognostic index.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

“…In patients with untreated CLL and DLBCL, increasing serum IL-10 levels were correlated with inferior survival [40]. Also, high levels of TNF in pre-treatment samples of NHL patients were correlated with poor outcome [36], and there was a significant decrease in serum TNF reported in low-grade NHL patients who achieved a complete response to standard chemotherapy [41]. In the current phase 1 study with a limited number of patients and samples, we found no correlation between levels of TNF or IL-10 and response to treatment.…”